多发性骨髓瘤中抗B细胞成熟抗原双特异性单克隆抗体感染报告风险增加：一项全球药物警戒研究。 - Suppr | 超能文献

相似文献

1

Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study.多发性骨髓瘤中抗B细胞成熟抗原双特异性单克隆抗体感染报告风险增加：一项全球药物警戒研究。

Am J Hematol. 2023 Dec;98(12):E349-E353. doi: 10.1002/ajh.27071. Epub 2023 Aug 30.

2

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。

Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.

3

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.单克隆抗体：治疗多发性骨髓瘤的最大资源。

Int J Mol Sci. 2023 Feb 5;24(4):3136. doi: 10.3390/ijms24043136.

4

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen.接受靶向B细胞成熟抗原的双特异性T细胞衔接器治疗的多发性骨髓瘤患者的持续性病毒感染

Haematologica. 2023 Nov 1;108(11):3186-3190. doi: 10.3324/haematol.2023.283003.

5

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.多发性骨髓瘤中双特异性抗体相关感染：系统评价和荟萃分析。

Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539.

6

Bispecific Antibodies for the Treatment of Multiple Myeloma.用于治疗多发性骨髓瘤的双特异性抗体

Curr Hematol Malig Rep. 2022 Dec;17(6):286-297. doi: 10.1007/s11899-022-00675-3. Epub 2022 Aug 27.

7

Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.嵌合抗原受体 T 细胞和双特异性抗体治疗多发性骨髓瘤期间感染预防的建议。

Br J Haematol. 2023 Dec;203(5):736-746. doi: 10.1111/bjh.18909. Epub 2023 Jun 7.

8

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.BCMA 靶向疗法治疗多发性骨髓瘤：最大化疗效和最小化不良事件的策略。

Expert Rev Hematol. 2022 Jun;15(6):503-517. doi: 10.1080/17474086.2022.2084068. Epub 2022 Jun 9.

9

An anti-B cell maturation antigen bispecific antibody for multiple myeloma.用于多发性骨髓瘤的抗 B 细胞成熟抗原双特异性抗体。

J Am Chem Soc. 2015 Apr 29;137(16):5288-91. doi: 10.1021/jacs.5b01876. Epub 2015 Apr 15.

10

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.BCMA-T 细胞双特异性抗体 EM801 用于多发性骨髓瘤治疗的靶表达、生成、临床前活性和药代动力学。

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.

引用本文的文献

1

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma.沉默信号：双特异性抗体治疗多发性骨髓瘤中出现的安全性问题

Front Med (Lausanne). 2025 Aug 13;12:1593405. doi: 10.3389/fmed.2025.1593405. eCollection 2025.

2

[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)].《BCMA双特异性T细胞衔接器治疗多发性骨髓瘤中国临床专家共识（2025年版）》

Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):209-215. doi: 10.3760/cma.j.cn121090-20250202-00050.

3

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review.